3D Pathology: A New Molecular Imaging Technique Wins World Molecular Imaging Congress VC Session
A Shark Tank session was held on Thursday evening September 13, 2018 at the WMIC in Seattle
Five venture capitalists and angel investors evaluated five different companies. Vivek Paul, Thomas J. Meade, PhD, Ajit Singh, PhD, David M. Hadley, PhD, and Brian Chow, PhD, unanimously chose Lightspeed Microscopy as a fundable start-up company with great potential for success.
Dr. Nick Reder, a pathologist at the University of Washington, along with CEO Dr. Steve Buckley, Dr. Adam Glaser, Professor Jonathan Liu, and Professor Larry True, co-founded Lightspeed Microscopy, a start-up company that manufactures a “flatbed scanner for tissue” that produces rich 3D molecular datasets. The ultimate goal of Lightspeed Microscopy is to replace traditional slide-based 2D pathology with molecular 3D pathology. This technique provides more and better data to help pathologists make critical patient decisions, all without consuming or destroying the tissue specimens.
“When I started residency, I could not believe pathology still used 2D glass slides when there is a better way. As we enter the age of AI in medicine, the ability to collect 3D molecular data from tissue samples is critical, it can be lifesaving. I believe this 3D data will allow us to unlock and advance our current level of knowledge and this could lead to better, more personalized patient care,” said Nick Reder, Co-Founder and Chief Scientific Officer of Lightspeed Microscopy.
